BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 22086901)

  • 1. Modulation of the central memory and Tr1-like regulatory T cells in multiple sclerosis patients responsive to interferon-beta therapy.
    Chiarini M; Serana F; Zanotti C; Capra R; Rasia S; Rottoli M; Rovaris M; Caputo D; Cavaletti G; Frigo M; Frigeni B; Clerici R; Rezzonico M; Caimi L; Imberti L
    Mult Scler; 2012 Jun; 18(6):788-98. PubMed ID: 22086901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon beta-induced restoration of regulatory T-cell function in multiple sclerosis is prompted by an increase in newly generated naive regulatory T cells.
    Korporal M; Haas J; Balint B; Fritzsching B; Schwarz A; Moeller S; Fritz B; Suri-Payer E; Wildemann B
    Arch Neurol; 2008 Nov; 65(11):1434-9. PubMed ID: 19001161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of IFN-beta therapy on the frequency and function of CD4(+)CD25(+) regulatory T cells and Foxp3 gene expression in relapsing-remitting multiple sclerosis (RRMS): a preliminary study.
    Namdar A; Nikbin B; Ghabaee M; Bayati A; Izad M
    J Neuroimmunol; 2010 Jan; 218(1-2):120-4. PubMed ID: 19932513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased IL-10 mRNA and IL-23 mRNA expression in multiple sclerosis: interferon-beta treatment increases IL-10 mRNA expression while reducing IL-23 mRNA expression.
    Krakauer M; Sorensen P; Khademi M; Olsson T; Sellebjerg F
    Mult Scler; 2008 Jun; 14(5):622-30. PubMed ID: 18424480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simultaneous quantification of natural and inducible regulatory T-cell subsets during interferon-β therapy of multiple sclerosis patients.
    Chiarini M; Capra R; Serana F; Bertoli D; Sottini A; Giustini V; Scarpazza C; Rovaris M; Torri Clerici V; Ferraro D; Galgani S; Solaro C; Conti MZ; Visconti A; Imberti L;
    J Transl Med; 2020 Apr; 18(1):169. PubMed ID: 32299447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopaminergic modulation of CD4+CD25(high) regulatory T lymphocytes in multiple sclerosis patients during interferon-β therapy.
    Cosentino M; Zaffaroni M; Trojano M; Giorelli M; Pica C; Rasini E; Bombelli R; Ferrari M; Ghezzi A; Comi G; Livrea P; Lecchini S; Marino F
    Neuroimmunomodulation; 2012; 19(5):283-92. PubMed ID: 22472872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD46 in a Spanish cohort of multiple sclerosis patients: genetics, mRNA expression and response to interferon-beta treatment.
    Alvarez-Lafuente R; Blanco-Kelly F; Garcia-Montojo M; Martínez A; De Las Heras V; Dominguez-Mozo MI; Bartolome M; Garcia-Martinez A; De la Concha EG; Urcelay E; Arroyo R
    Mult Scler; 2011 May; 17(5):513-20. PubMed ID: 21177319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IFNbeta-1a therapy for multiple sclerosis expands regulatory CD8+ T cells and decreases memory CD8+ subset: a longitudinal 1-year study.
    Aristimuño C; de Andrés C; Bartolomé M; de las Heras V; Martínez-Ginés ML; Arroyo R; Fernández-Cruz E; Sánchez-Ramón S
    Clin Immunol; 2010 Feb; 134(2):148-57. PubMed ID: 19900844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenic effects of recombinant interferon-beta therapy disrupt the JAK/STAT pathway in primary immune cells from patients with multiple sclerosis.
    Gavasso S; Gjertsen B; Anderssen E; Myhr K; Vedeler C
    Mult Scler; 2012 Aug; 18(8):1116-24. PubMed ID: 22287540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A defect of CD4+CD25+ regulatory T cells in inducing interleukin-10 production from CD4+ T cells under CD46 costimulation in asthma patients.
    Xu YQ; Gao YD; Yang J; Guo W
    J Asthma; 2010 May; 47(4):367-73. PubMed ID: 20528588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced production of noggin by immune cells of patients with relapsing-remitting multiple sclerosis.
    Urshansky N; Mausner-Fainberg K; Auriel E; Regev K; Bornstein NM; Karni A
    J Neuroimmunol; 2011 Mar; 232(1-2):171-8. PubMed ID: 21111488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of interferon-beta on co-signaling molecules: upregulation of CD40, CD86 and PD-L2 on monocytes in relation to clinical response to interferon-beta treatment in patients with multiple sclerosis.
    Wiesemann E; Deb M; Trebst C; Hemmer B; Stangel M; Windhagen A
    Mult Scler; 2008 Mar; 14(2):166-76. PubMed ID: 17942524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renewal of the T-cell compartment in multiple sclerosis patients treated with glatiramer acetate.
    Chiarini M; Sottini A; Ghidini C; Zanotti C; Serana F; Rottoli M; Zaffaroni M; Bergamaschi R; Cordioli C; Capra R; Imberti L
    Mult Scler; 2010 Feb; 16(2):218-27. PubMed ID: 20007428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis.
    Mehling M; Lindberg R; Raulf F; Kuhle J; Hess C; Kappos L; Brinkmann V
    Neurology; 2010 Aug; 75(5):403-10. PubMed ID: 20592255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of neutralizing antibodies to therapeutic interferon-beta in multiple sclerosis patients: a comparison of three methods in a large Australasian cohort.
    McKay F; Schibeci S; Heard R; Stewart G; Booth D
    J Immunol Methods; 2006 Mar; 310(1-2):20-9. PubMed ID: 16448664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The balance of pro-inflammatory and trophic factors in multiple sclerosis patients: effects of acute relapse and immunomodulatory treatment.
    Lindquist S; Hassinger S; Lindquist JA; Sailer M
    Mult Scler; 2011 Jul; 17(7):851-66. PubMed ID: 21561957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dysfunction of IL-10-producing type 1 regulatory T cells and CD4(+)CD25(+) regulatory T cells in a mimic model of human multiple sclerosis in Cynomolgus monkeys.
    Ma A; Xiong Z; Hu Y; Qi S; Song L; Dun H; Zhang L; Lou D; Yang P; Zhao Z; Wang X; Zhang D; Daloze P; Chen H
    Int Immunopharmacol; 2009 May; 9(5):599-608. PubMed ID: 19539557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alterations in CD46-mediated Tr1 regulatory T cells in patients with multiple sclerosis.
    Astier AL; Meiffren G; Freeman S; Hafler DA
    J Clin Invest; 2006 Dec; 116(12):3252-7. PubMed ID: 17099776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dynamic T-lymphocyte chemokine receptor expression induced by interferon-beta therapy in multiple sclerosis.
    Krakauer M; Sorensen PS; Khademi M; Olsson T; Sellebjerg F
    Scand J Immunol; 2006 Aug; 64(2):155-63. PubMed ID: 16867161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon-beta increases systemic BAFF levels in multiple sclerosis without increasing autoantibody production.
    Hedegaard CJ; Sellebjerg F; Krakauer M; Hesse D; Bendtzen K; Nielsen CH
    Mult Scler; 2011 May; 17(5):567-77. PubMed ID: 21177756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.